This phase III trial evaluated the addition of carboplatin to neoadjuvant chemotherapy in triple-negative breast cancer. The addition improved overall survival, particularly in premenopausal women, but did not significantly impact event-free survival. The treatment was well tolerated, with manageable toxicities.
Study
|
Phase III randomized controlled trial [CTRI/2012/07/002802] |
| Triple-negative breast cancer, premenopausal and postmenopausal women |
| Carboplatin+Paclitaxel (n=361) vs Paclitaxel (n=356) for 8 weeks, then anthracycline-cyclophosphamide
|
Efficacy
|
5-year EFS: 70.7% vs 64.1%; HR 0.80 [0.62-1.03] |
| 5-year OS: 74.4% vs 66.8%; HR 0.74 [0.57-0.97] |
| Premenopausal: 5-year EFS: 75.0% vs 59.6%; HR 0.61 [0.43-0.84] |
| Premenopausal: 5-year OS: 78.2% vs 64.6%; HR 0.57 [0.40-0.82]
|
Safety
|
Grade >=3 myelosuppression and neutropenic fever (14.7% vs 12.9%) |
| Nonhematologic toxicities were not significantly different.
|
J Clin Oncol. Published online October 20, 2025
Gupta S, Nair N, Hawaldar R New Reference: Neoadjuvant Carboplatin for Triple-Negative Breast Cancer
http://doi.org/10.1200/JCO-25-01023
Reviewed by Ulas D. Bayraktar, MD on Nov 13, 2025
